Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Randomised, Double Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Compared to Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin Monotherapy

NCT01006603 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01006603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01006603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Randomised, Double Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Compared to Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin Monotherapy
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2009
Completion date
June 30, 2012
Enrollment
957 (actual)
Sites
131

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus